Peder E. Z. Larson1, Galen D. Reed, Adam B. Kerr2, John M. Pauly2, Robert Bok, Marcus Ferrone, Andrea Harzstark, Sarah J. Nelson, John Kurhanewicz, Daniel B. Vigneron
1UCSF, San Francisco, CA, United States; 2Stanford University
As part of the first hyperpolarized [1-13C]-pyruvate clinical trial, we developed a specialized dynamic 13C 2D EPSI sequence using short multiband pulses, and applied it in four prostate cancer patients. Time-resolved MR spectroscopic imaging (MRSI) following injection of hyperpolarized [1-13C]-pyruvate can provide valuable and detailed metabolic information, including perfusion, uptake and kinetics. We observed SNRs up to 340 for pyruvate within 15-20 sec after injection, and SNRs up to 17 for lactate within 25-35 sec after injection. The signal lasted for up to 75 sec for pyruvate and 70 sec for lactate.